Published in Pharma Law Weekly, February 20th, 2007
Affectis will develop the compound, named Cimicoxib, as a treatment for depression and schizophrenia. The company expects to start a phase II trial in depression with Cimicoxib this year.
Cimicoxib has already finished phase IIa trials in pain. At present, coxibs are approved for adult rheumatic conditions including osteoarthritis, rheumatoid arthritis and ankylosing spondylitis as well as for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly